Leading Expert Andrei Breazna Adds Depth to Quartesian Biostatistics Team

PRINCETON, N.J., June 12, 2019 /PRNewswire/ — Quartesian, a multinational Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced the appointment of Andrei Breazna, Ph.D. as Worldwide Head of Statistics. This addition strengthens Quartesian’s expertise in analytics, statistics and programming and adds significant statistical therapeutic experience.

With a career spanning 20 years, Andrei Breazna is a recognized expert in the analysis of Hematology, Cardiovascular, Metabolic Disorders, Oncology, and Neurology trial results, and is an author in nearly 30 journal articles and abstracts. Prior to joining Quartesian, he served as Director of Statistics at Pfizer Inc. He has also held senior roles of increasing responsibility with GlaxoSmithKline and the FDA.

“Biostatistics is at the core of every clinical study from design, through protocol development, to analysis and reporting As such, it is a vital component of our service offerings,” said Benjamin Jackson, CEO of Quartesian. “Andrei’s expert knowledge and reputation will lead Quartesian’s expansion of our bio-statistical consulting and services capabilities.”

“I’m pleased to join Quartesian and advance the work of a first-class Statistics and Data Analytics operation,” said Andrei Breazna. “The team has built an excellent reputation for quality and efficiency that I am proud to be a part of.”

Andrei will participate at the upcoming DIA Annual Meeting with Quartesian at Booth #2409 and will be available to meet regarding any of Quartesian’s bio-statistical consulting and services for pre-clinical, clinical, registration phase, and post-marketing studies, including regulatory submission and agency meeting representation.

About Quartesian
Quartesian was formed in January 2003 and is headquartered in Princeton, N.J. with the goal of providing “Clinical Data Your Way” to its clients. This goal is accomplished by providing clinical data services faster, more efficient and cost-effective than ever thought possible. The founding members of Quartesian rely not only on their technical expertise, but also on their experience as past clients of clinical service providers. Quartesian prides itself on its flexibility, responsiveness, adherence to client specifications and timelines for all projects conducted anywhere in the world. We have worked with over 135+ pharmaceutical, biotechnology, generic, and medical device companies with 100% repeat business track record and no change orders.  Learn more about Quartesian at www.quartesian.com

Media Contact: 
Stephen Boccardo
Sr. VP Business Development and Commercial Strategy
609.454.3312 ext 113
stephen.boccardo@quartesian.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/leading-expert-andrei-breazna-adds-depth-to-quartesian-biostatistics-team-300866134.html

SOURCE Quartesian

Staff

Recent Posts

Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes

Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United…

20 mins ago

Universal Recall Platform Alliance Launches to Keep Patients Safe

Industry initiative URPA broadens calls to improve speed, accuracy of recall communicationWEST HOLLYWOOD, CA /…

21 mins ago

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual…

3 hours ago

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…

3 hours ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by…

3 hours ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading…

3 hours ago